Score Breakdown
Below average.
Kodiak Sciences is a binary clinical-stage biotech with no revenue, high cash burn (~$55M/quarter), and a 72x P/B ratio. The Dec 2025 capital raise extended runway to 2H 2027 but at massive dilution. The investment case is entirely a bet on Phase 3 readouts for tarcocimab (GLOW2 in Q1 2026) and KSI-501 (DAYBREAK in Q3 2026). The $1.3B market cap embeds meaningful probability of success, but given the prior Phase 3 failure in DME, intense competition from Vabysmo/Eylea, and the company's history of clinical disappointments, the risk/reward is roughly balanced. The CFO's adoption of a sell plan during going concern disclosure is a notable negative signal. High short interest (14.9%) creates potential squeeze dynamics but also reflects informed skepticism. At $24.86, the stock prices in perhaps a 25-30% probability of major commercial success, which seems approximately fair given the pipeline breadth but offset by execution risk and competitive pressure. There are better risk/reward setups elsewhere.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Slow bleed.
Neutral.
Tight but ok.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The bear thesis relies on the traumatic August 2023 failure of tarcocimab in diabetic macular edema (DME), which decimated the stock price. Bears argue the company is a 'one-platform' risk with no revenue and a history of over-promising. Despite the recent capital raise, KOD still maintains a high net loss ($54.3M in Q2 2025) and a Price-to-Book ratio of ~72x, which is significantly higher than the biotech industry average of 2.7x (Simply Wall St, Feb 2026).
🔍 What's In The SEC Filings
Kodiak is a liquidity-constrained clinical entity whose survival depends entirely on near-term capital raises as cash reserves provide less than 12 months of runway at current burn rates.
Management has issued an explicit warning regarding the company's ability to survive the next 12 months.
“As a result, there is substantial doubt regarding the Company's ability to continue as a going concern.”
Operating cash burn of $40 million per quarter against a cash balance of $169.5 million leaves the company with roughly 4.2 quarters of remaining life without immediate dilutive financing.
The company has a massive overhang of anti-dilutive securities that will crush common shareholders upon any recovery.
“Total [common share equivalents excluded] 22,193,161”
With 62.1 million shares outstanding, the 22.2 million excluded options and awards represent a potential 35.7% dilution that is currently 'hidden' from basic EPS calculations but looms over the capital structure.
A $100 million liability exists for future royalties, representing a significant encumbrance on future revenues.
“the fair value of the liability related to sale of future royalties is based on the Company's current estimates of future royalties expected to be paid to Baker Bros. Advisors, LP (“BBA”), which are considered Level 3 inputs.”
This creates a non-traditional debt-like obligation where management uses subjective Level 3 inputs to estimate payments to an insider-linked firm, potentially prioritizing these payments over other obligations.
Management continues to issue heavy stock-based compensation despite a liquidity crisis and 10-Q going concern warnings.
“Total stock-based compensation: $12,155 [thousand]”
Stock-based compensation accounts for approximately 20% of total operating expenses, suggesting management is protecting their personal upside while the company’s cash-pay ability is terminal.
The intrinsic value should be discounted by at least 50% from cash-on-hand to account for the immediate necessity of highly dilutive financing and the preferential royalty claim by Baker Bros.
The sublease of their 1200 Page Mill Road facility and a $1.9 million impairment charge suggest desperate cost-cutting measures and a reduction in physical operational footprint.